This morning, CB2 Insights (CSE: CBII) announced it has entered into an agreement with that of Vivo Cannabis Inc (TSXV: VIVO). The joint partnership will be focused on ensuring that Vivo’s current products meet potency criteria as well as safety requirements through the use of CB2’s technology.
CB2 Insights is a contract research firm focused on cannabis. The issuer is comprised of three divisions, including clinical operations, technology and analytics, and research and development. The company’s two main programs, electronic data capture (EDC) and clinical data management system (CDMS), are used to gather and analyze data from clinical trials and client operations.
As per the agreement, CB2 Insights will provide Vivo with analytics technology and research services in order to ensure Vivo’s products uphold Canadian cannabis regulations, as well as meet cannabis patient demands. Both of CB2’s programs are anticipated to be implemented at Vivo’s facilities as a result.
The agreement is set to take a multi-phased approach in the validation and quality assurance of current products. Conclusively, the project will be used to support the advancement of Vivo’s forthcoming cannabis products.
Vivo Cannabis is currently trading at $0.30 on the TSXV.
Information for this briefing was found via Sedar, CB2 insights and Vivo Cannabis. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.